You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 576 NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immune-stimulants and immune modulators
576 NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020230015
Dec 20203406
Jan 20212506
Feb 202134014
Mar 202138011
Apr 20213803
May 20211309
Jun 20210015
Jul 20210011
Aug 2021006
Sep 20210012
Oct 202142037
Nov 202138023
Dec 202132014
Jan 202230015
Feb 202234012
Mar 20223607
Apr 20225009
May 20221600
Jun 20222402
Jul 20221601
Aug 20222805
Sep 20221601
Oct 20222205
Nov 20223805
Dec 20223101
Jan 20232002
Feb 20231602
Mar 20232803
Apr 20233608
May 20232205
Jun 20231803
Jul 20231004
Aug 20231007
Sep 2023802
Oct 2023603
Nov 20232602
Dec 20232002
Jan 2024600
Feb 20241200
Mar 20242002
Apr 20242003
May 20243306
Jun 20244603
Jul 20242609
Aug 20241602
Sep 20242402
Total12880315